Work

Phase II study of amrubicin, a new active drug in refractory or relapsed small-cell lung cancer (SCLC): Thoracic Oncology Research Group Trial 0301

Year: 2006

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2006.24.18_suppl.7060

Authors: T. Seto, N. Masuda, Y. Takiguchi, H. Isobe, H. Okamoto, T. Ogura, A. Yokoyama, K. Watanabe, K. Eguchi

Institutions: Tokai University, Chiba University, Niigata Cancer Center Hospital, Yokohama Municipal Citizen's Hospital, Kanagawa Cardiovascular and Respiratory Center, Kitasato University

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2275475258

Cites:

Cited by: 5

Related to: 10